#005Recovery

>99.6%

TB-500

Thymosin Beta-4 Synthetic Fragment

Half-life: ~3–7 days (estimated)

Tβ4Thymosin β4 fragmentThymosin B4

Research Profile

Research Depth

Potency

Half-Life Score

Selectivity

Stability

Relative research assessments — educational reference only.

Target Receptors

G-actin (direct binding)integrin-linked kinase

Buying peptides in Bali?

See community-reported Bali price ranges for TB-500 and 9 other compounds — clinic menus, WhatsApp quotes and import realities.

Open the Bali Price Index →

Critical Research Warning

Animal research data only. No human RCTs completed. The full systemic effects of chronic Thymosin Beta-4 administration are unknown.

PeptidePlaza Entry #005

"A synthetic fragment of Thymosin Beta-4, a ubiquitous actin-sequestering protein. Research focuses on promoting tissue repair, reducing inflammation, and supporting angiogenesis in cardiac and skeletal muscle models."

Full Description

TB-500 corresponds to the actin-binding domain of Thymosin Beta-4 (Tβ4), a highly conserved 43-amino acid protein expressed in virtually all human cells. Tβ4 is one of the most abundant proteins in mammalian cytoplasm. TB-500 shares the core LKKTET motif responsible for G-actin sequestration. Research demonstrates promotion of endothelial cell migration and angiogenesis, keratinocyte migration for wound closure, cardiac progenitor cell activation, and anti-inflammatory activity. Cardiac repair studies in rodents show improved post-infarct recovery with Tβ4 administration.

Mechanism of Action

Sequesters G-actin via LKKTET motif, regulating cytoskeletal dynamics and cell migration. Promotes endothelial progenitor mobilization from bone marrow, upregulates MMP-2, reduces inflammatory cytokines.

Reported Benefits

• Promotes endothelial cell migration and angiogenesis
• Accelerated wound closure and keratinocyte migration
• Cardiac protection post-infarction in animal models
• Anti-inflammatory effects via cytokine modulation

Potential Side Effects

• Injection site discomfort and erythema
• Mild fatigue reported in some protocols
• Potential for excessive angiogenesis (theoretical)
• Headache in a subset of subjects

Frequently Asked Questions

How does TB-500 differ from BPC-157 for tissue repair?▼

While both promote healing, TB-500 works primarily through actin cytoskeleton regulation and cell migration, whereas BPC-157 acts more broadly through angiogenesis and growth factor sensitization. TB-500 has a longer half-life (~3–7 days vs ~4 hours), making dosing less frequent in research protocols.

What does the cardiac repair research show?▼

Landmark Nature studies show Tβ4 can activate dormant epicardial progenitor cells in the heart, causing them to migrate and form new cardiomyocytes after a heart attack in mice — a finding with significant implications for cardiac regeneration research.

For Research Reference Only

Not medical advice. Peptides may be regulated or restricted in your jurisdiction.

References

1.Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. PubMed (2026). Di H, et al.. pubmed.ncbi.nlm.nih.gov/41570941/ ↑
2.Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. PubMed (2025). Zhang Y, et al.. pubmed.ncbi.nlm.nih.gov/41229390/ ↑
3.Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals. PubMed (2025). Maar K, et al.. pubmed.ncbi.nlm.nih.gov/40362372/ ↑
4.Inhaled exogenous thymosin beta 4 suppresses bleomycin-induced pulmonary fibrosis in mice via TGF-β1 signalling pathway. PubMed (2025). Yu R, et al.. pubmed.ncbi.nlm.nih.gov/39579076/ ↑

Where to Source TB-500

42 vendors listed · ranked most → least trusted · not an endorsement

Verified Unverified

Community Top Pick

NovaPeptide Labs Verified

4.9(847 reviews)

🇺🇸USA